{"id":34601,"date":"2025-06-03T17:11:03","date_gmt":"2025-06-03T09:11:03","guid":{"rendered":"https:\/\/flcube.com\/?p=34601"},"modified":"2025-06-03T17:11:04","modified_gmt":"2025-06-03T09:11:04","slug":"nurix-therapeutics-announces-sanofis-acquisition-of-stat6-program-rights","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34601","title":{"rendered":"Nurix Therapeutics Announces Sanofi’s Acquisition of STAT6 Program Rights"},"content":{"rendered":"\n

US-based Nurix Therapeutics, Inc. (NASDAQ: NRIX<\/a>) announced that Sanofi (NASDAQ: SNY<\/a>), a major French pharmaceutical company, has exercised its option to acquire exclusive global rights to Nurix’s STAT6 program, which includes the investigational candidate NX-3911. NX-3911 is an oral, highly selective STAT6 degrader designed to treat type 2 inflammation-related diseases by inhibiting STAT6 signaling.<\/p>\n\n\n\n

Collaboration Background<\/strong>
This decision stems from a collaboration agreement signed in December 2019. Under the agreement, Sanofi utilized Nurix’s proprietary DEL-AI drug discovery platform to develop targeted protein degradation (TPD) therapies. The original deal included options for Sanofi to co-develop and co-promote up to two potential products. Sanofi made an upfront payment of USD 55 million and an additional USD 22 million to expand the collaboration scope. Previously, Sanofi exercised its first option for an undisclosed TPD asset in April this year.<\/p>\n\n\n\n

Financial Details<\/strong>
With this latest move, Nurix will receive a USD 15 million license extension fee, bringing the total payments from Sanofi to USD 127 million to date. Nurix is also eligible for up to USD 465 million in additional milestone payments tied to the STAT6 program, along with potential sales royalties. The company retains an option for U.S. co-development and co-promotion rights.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US-based Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced that Sanofi (NASDAQ: SNY), a major French pharmaceutical…<\/p>\n","protected":false},"author":1,"featured_media":34602,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1156,867,1084,147,70],"class_list":["post-34601","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-nasdaq-nrix","tag-nasdaq-sny","tag-nurix-therapeutics","tag-sanofi","tag-tpd"],"yoast_head":"\nNurix Therapeutics Announces Sanofi's Acquisition of STAT6 Program Rights - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced that Sanofi (NASDAQ: SNY), a major French pharmaceutical company, has exercised its option to acquire exclusive global rights to Nurix's STAT6 program, which includes the investigational candidate NX-3911. NX-3911 is an oral, highly selective STAT6 degrader designed to treat type 2 inflammation-related diseases by inhibiting STAT6 signaling.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34601\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nurix Therapeutics Announces Sanofi's Acquisition of STAT6 Program Rights\" \/>\n<meta property=\"og:description\" content=\"US-based Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced that Sanofi (NASDAQ: SNY), a major French pharmaceutical company, has exercised its option to acquire exclusive global rights to Nurix's STAT6 program, which includes the investigational candidate NX-3911. NX-3911 is an oral, highly selective STAT6 degrader designed to treat type 2 inflammation-related diseases by inhibiting STAT6 signaling.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34601\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-03T09:11:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-03T09:11:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0308.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34601#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34601\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Nurix Therapeutics Announces Sanofi’s Acquisition of STAT6 Program Rights\",\"datePublished\":\"2025-06-03T09:11:03+00:00\",\"dateModified\":\"2025-06-03T09:11:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34601\"},\"wordCount\":209,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34601#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0308.webp\",\"keywords\":[\"NASDAQ: NRIX\",\"NASDAQ: SNY\",\"Nurix Therapeutics\",\"Sanofi\",\"TPD\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34601#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34601\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34601\",\"name\":\"Nurix Therapeutics Announces Sanofi's Acquisition of STAT6 Program Rights - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34601#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34601#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0308.webp\",\"datePublished\":\"2025-06-03T09:11:03+00:00\",\"dateModified\":\"2025-06-03T09:11:04+00:00\",\"description\":\"US-based Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced that Sanofi (NASDAQ: SNY), a major French pharmaceutical company, has exercised its option to acquire exclusive global rights to Nurix's STAT6 program, which includes the investigational candidate NX-3911. NX-3911 is an oral, highly selective STAT6 degrader designed to treat type 2 inflammation-related diseases by inhibiting STAT6 signaling.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34601#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34601\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34601#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0308.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0308.webp\",\"width\":1080,\"height\":608,\"caption\":\"Nurix Therapeutics Announces Sanofi's Acquisition of STAT6 Program Rights\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34601#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nurix Therapeutics Announces Sanofi’s Acquisition of STAT6 Program Rights\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Nurix Therapeutics Announces Sanofi's Acquisition of STAT6 Program Rights - Insight, China's Pharmaceutical Industry","description":"US-based Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced that Sanofi (NASDAQ: SNY), a major French pharmaceutical company, has exercised its option to acquire exclusive global rights to Nurix's STAT6 program, which includes the investigational candidate NX-3911. NX-3911 is an oral, highly selective STAT6 degrader designed to treat type 2 inflammation-related diseases by inhibiting STAT6 signaling.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34601","og_locale":"en_US","og_type":"article","og_title":"Nurix Therapeutics Announces Sanofi's Acquisition of STAT6 Program Rights","og_description":"US-based Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced that Sanofi (NASDAQ: SNY), a major French pharmaceutical company, has exercised its option to acquire exclusive global rights to Nurix's STAT6 program, which includes the investigational candidate NX-3911. NX-3911 is an oral, highly selective STAT6 degrader designed to treat type 2 inflammation-related diseases by inhibiting STAT6 signaling.","og_url":"https:\/\/flcube.com\/?p=34601","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-03T09:11:03+00:00","article_modified_time":"2025-06-03T09:11:04+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0308.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34601#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34601"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Nurix Therapeutics Announces Sanofi’s Acquisition of STAT6 Program Rights","datePublished":"2025-06-03T09:11:03+00:00","dateModified":"2025-06-03T09:11:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34601"},"wordCount":209,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34601#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0308.webp","keywords":["NASDAQ: NRIX","NASDAQ: SNY","Nurix Therapeutics","Sanofi","TPD"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34601#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34601","url":"https:\/\/flcube.com\/?p=34601","name":"Nurix Therapeutics Announces Sanofi's Acquisition of STAT6 Program Rights - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34601#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34601#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0308.webp","datePublished":"2025-06-03T09:11:03+00:00","dateModified":"2025-06-03T09:11:04+00:00","description":"US-based Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced that Sanofi (NASDAQ: SNY), a major French pharmaceutical company, has exercised its option to acquire exclusive global rights to Nurix's STAT6 program, which includes the investigational candidate NX-3911. NX-3911 is an oral, highly selective STAT6 degrader designed to treat type 2 inflammation-related diseases by inhibiting STAT6 signaling.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34601#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34601"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34601#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0308.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0308.webp","width":1080,"height":608,"caption":"Nurix Therapeutics Announces Sanofi's Acquisition of STAT6 Program Rights"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34601#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Nurix Therapeutics Announces Sanofi’s Acquisition of STAT6 Program Rights"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0308.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34601","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34601"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34601\/revisions"}],"predecessor-version":[{"id":34603,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34601\/revisions\/34603"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34602"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34601"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34601"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34601"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}